Celgene (NASDAQ:CELG) has been assigned a $112.00 target price by analysts at Cantor Fitzgerald in a note issued to investors on Thursday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 3.82% from the stock’s previous close.
Several other research analysts have also recently issued reports on CELG. Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective for the company. in a research note on Monday. BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Piper Jaffray Companies restated a “hold” rating on shares of Celgene in a research note on Sunday, December 10th. Leerink Swann restated a “buy” rating and issued a $120.00 price objective on shares of Celgene in a research note on Wednesday, December 13th. Finally, Oppenheimer set a $166.00 price objective on Celgene and gave the stock a “buy” rating in a research note on Thursday, December 14th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and an average target price of $136.21.
Shares of Celgene (CELG) opened at $107.88 on Thursday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a market capitalization of $84,940.00, a PE ratio of 16.92, a price-to-earnings-growth ratio of 0.84 and a beta of 1.77.
In other news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.95% of the company’s stock.
Large investors have recently modified their holdings of the company. Thompson Davis & CO. Inc. boosted its stake in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI boosted its stake in shares of Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the last quarter. Robecosam AG purchased a new position in Celgene during the third quarter worth approximately $114,000. Guidant Wealth Advisors purchased a new position in Celgene during the third quarter worth approximately $119,000. Finally, Capital Bank & Trust Co lifted its position in Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 517 shares in the last quarter. 79.84% of the stock is currently owned by hedge funds and other institutional investors.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
